WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Prescribed drugs, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology firm devoted to creating small molecule medication for virology and immunology indications, as we speak introduced that Jay R. Luly, Ph.D., President and Chief Govt Officer, and Tara L. Kieffer, Ph.D., Chief Product Technique Officer, will take part in a fireplace chat on the Jefferies International Healthcare Convention on June 5, 2024 at 7:30 a.m. ET in New York, NY.
A reside webcast of the occasion shall be accessible by visiting the Occasions and Displays part on the Traders web page of Enanta’s web site at www.enanta.com. A replay of the webcast shall be accessible following the presentation and shall be archived for a minimum of 30 days.
About Enanta Prescribed drugs (NASDAQ:), Inc.
Enanta is utilizing its sturdy, chemistry-driven strategy and drug discovery capabilities to turn out to be a pacesetter within the discovery and improvement of small molecule medication for virology and immunology indications. Enanta’s analysis and improvement applications are at the moment centered on respiratory syncytial virus (RSV) and persistent spontaneous urticaria (CSU) and the corporate has beforehand superior clinical-stage compounds for SARS-CoV-2 (COVID-19) and persistent hepatitis B virus (HBV) an infection.
Glecaprevir, a protease inhibitor found by Enanta, is a part of one of many main remedy regimens for curing persistent hepatitis C virus an infection (HCV) and is bought by AbbVie (NYSE:) in quite a few international locations beneath the commerce names MAVYRET ®(U.S.) and MAVIRET ®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV merchandise developed beneath its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please go to http://www.enanta.com for extra data.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240529474424/en/
Media and Traders:
Jennifer Viera
jviera@enanta.com
Supply: Enanta Prescribed drugs, Inc.
